MorphoSys sees another year of rising R&D spending

MorphoSys AG expects to see another year of heavy investment in its proprietary antibody portfolio as the pace of early-clinical stage development quickens. In 2011, proprietary R&D spending is expected to rise by about 50%, the company announced.